A central role of IKK2 and TPL2 in JNK activation and viral B-cell transformation

Stefanie Voigt1, Kai R. Sterz1, Fabian Giehler1,2, Anne-Wiebe Mohr1,2, Joanna B. Wilson3, Andreas Moosmann1,2,4 & Arnd Kieser1,2*

IκB kinase 2 (IKK2) is well known for its pivotal role as a mediator of the canonical NF-κB pathway, which has important functions in inflammation and immunity, but also in cancer. Here we identify a novel and critical function of IKK2 and its co-factor NEMO in the activation of oncogenic c-Jun N-terminal kinase (JNK) signaling, induced by the latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV). Independent of its kinase activity, the TGFβ-activated kinase 1 (TAK1) mediates LMP1 signaling complex formation, NEMO ubiquitination and subsequent IKK2 activation. The tumor progression locus 2 (TPL2) kinase is induced by LMP1 via IKK2 and transmits JNK activation signals downstream of IKK2. The IKK2-TPL2-JNK axis is specific for LMP1 and differs from TNFα, Interleukin-1 and CD40 signaling. This pathway mediates essential LMP1 survival signals in EBV-transformed human B cells and post-transplant lymphoma, and thus qualifies as a target for treatment of EBV-induced cancer.

1Helmholtz Centre Munich - German Research Centre for Environmental Health, Research Unit Gene Vectors, Marchioninistrasse 25, 81377 Munich, Germany. 2German Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany. 3School of Life Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK. 4Faculty of Medicine, Ludwig-Maximilians-University Munich, Grosshadern, Marchioninistrasse 25, 81377 Munich, Germany. *email: a.kieser@helmholtz-muenchen.de
The latent membrane protein 1 (LMP1) serves as the prototype of a herpesviral oncoprotein. It is expressed by Epstein-Barr virus (EBV), a γ-herpesvirus causing lymphoproliferative and malignant diseases in humans. LMP1 critically contributes to the pathogenesis of B-cell-derived infectious mononucleosis, Hodgkin’s lymphoma and fatal post-transplant lymphoproliferative disease (PTLD), as well as playing an important role in the development of EBV-associated nasopharyngeal carcinoma. B cell transformation by the virus depends on LMP1, which mimics stimulatory signals usually provided by the CD40 receptor. LMP1 causes oncogenic cell transformation in rodent fibroblasts and LMP1-transgenic mice develop hyperproliferation and inflammation, or malignancies, dependent on the tissue and cell type, in which the viral oncogene is expressed.

Functioning as constitutively active receptor, LMP1 deregulates cellular pathways involved in proliferation and survival signaling including NF-κB, PI3-kinase, and the MAP kinases c-Jun N-terminal kinase (JNK), ERK and p38. LMP1 consists of a short N-terminal region linked to six transmembrane helices, which mediate LMP1 activation by spontaneous autoggregation. The C-terminal cytoplasmic domain (amino acids 187–386) harbors the C-terminal activator regions one (CTAR1, aa 194–232) and two (CTAR2, aa 351–386), which are both required for viral cell transformation. Similar to TNF receptors (TNFR) or members of the Interleukin-1/Toll-like receptor (IL-1/TLR) family, LMP1 recruits TNFR-associated factors (TRAFs), TRAF1, 2, and 3 directly bind to CTAR1, the region that induces noncanonical NF-κB, PI3-kinase, and MAPK signaling. CTAR2 recruits TRAF6 and the TNFR-associated death domain protein (TRADD) to activate canonical NF-κB and JNK as the primary readouts of this subdomain. Both CTAR2-induced pathways are required for proliferation and survival of EBV-transformed B cells. TRAF6 is essential for CTAR2 function. It possesses lysine 63-linked ubiquitin ligase activity. Accordingly, K63-linked, but also linear ubiquitin chains, are important for LMP1 downstream signaling. The Ste20 germinal center kinase TNIK, the transforming growth factor-β-activated kinase 1 (TAK1), and the TAK1 binding proteins (TAB) 1–3 are involved in JNK and canonical NF-κB signaling downstream of TRAF6.

The transcription factor NF-κB is a key regulator of inflammation and immunity, which is often found deregulated in lymphoid malignancies and other cancer types. The canonical NF-κB pathway converges with the noncanonical pathway at the IκB kinase (IKK) complex, which is also the case in LMP1 signal transduction. The IKK complex comprises two catalytic components, IKK1 (also named IκKa) and IKK2 (IκKb). The regulatory factor NEMO (IκKy) is essential for the canonical NF-κB pathway and acts by binding and activating IKK2 dimers. IKK2 requires phosphorylation within its activation loop to be active. TAK1 can phosphorylate IKK2 at serine 177, which is a priming event for IKK2 autophosphorylation at serine 181, resulting in IKK2 activation in IL-1 signaling. IKK2 in turn phosphorylates IκBa, whose consequent degradation leads to the liberation and nuclear translocation of canonical NF-κB dimers containing the transcription factor p65 NF-κB. IKK2 is essential for NF-κB induction by LMP1-CTAR2 in most situations. Functions of IKK2 in LMP1-mediated or cellular JNK signaling have not been reported.

The serine/threonine kinase TPL2 (tumor progression locus 2), also known as Cot or MAP3K8, plays an important role in inflammation, immunity and tumorigenesis. TPL2 primarily activates the ERK pathway in response to various stimuli including cytokines, growth factors or stress. CD40 relies on TPL2 to activate ERK. In some cell types, TPL2 contributes to the optimal activation of p38 MAPK and JNK, specifically in response to genotoxic stress or inflammatory stimuli such as TNFα or IL-1β. TPL2 crosstalks to the NF-κB pathway. In its inactive state, TPL2 protein is stabilized and inhibited by complex formation with the IκB protein p105, the precursor of p50 NF-κB. Upon agonist stimulation, p105 is phosphorylated by IKK2, which causes p105 degradation and subsequent TPL2 activation and destabilization. Activation-induced p105 degradation releases Rel subunits complexed with p105. Further, a non-essential role of TPL2 in NF-κB signaling by LMP1 has been suggested.

Precise knowledge of the LMP1 signaling network is a prerequisite for its exploitation as a target for the treatment of EBV-associated cancer. However, the molecular mechanisms of CTAR2 signaling in particular are not fully understood. In addition to the architecture of the CTAR2 complex itself, the contributions of signaling mediators such as IKKs, TAK1 or TPL2 are insufficiently defined or controversial. Here we investigate the functions of IKK2 in CTAR2 signaling and discover an unexpected and critical role of this IKK isoform in JNK activation by LMP1. TPL2 transmits JNK activation signals downstream of IKK2, which is a new role for this MAP3K in cellular signaling. The IKK2-TPL2-JNK pathway mediates survival and proliferation of EBV-transformed B cells and of LMP1-expressing primary tumor cells established from PTLD biopsies. Our results extend the biological functions of IKK2 and TPL2 to a critical role in JNK activation.

Results

Genetic analysis of IKK2 function in LMP1-CTAR2 signaling. To investigate the role of IKK2 in the LMP1 signaling network we transduced wildtype and IKK2−/− mouse embryonic fibroblasts (MEFs) with NGFR-LMP1, a fusion protein of the extracellular and transmembrane domains of p75 NGF-receptor and the signaling domain of LMP1. NGFR-LMP1(Y384G) harboring an inactivated CTAR2 was included to define the pathways that are initiated at this subdomain. Equivalent surface expression of the NGFR-LMP1 chimera was confirmed by flow cytometry. NGFR-LMP1 chimeras triggered the fast response of JNK and canonical NF-κB (Fig. 1c). The Y384G mutant failed to induce both pathways, demonstrating that JNK and canonical NF-κB are activated at CTAR2. However, NGFR-LMP1(Y384G) was still able to induce the depletion of TRAF3 from NF-κB-activated signaling events. NGFR-LMP1(Y384G) harboring an inactivated CTAR2 was included to define the pathways that are initiated at this subdomain. Equivalent surface expression of the NGFR-LMP1 chimera was confirmed by flow cytometry. In examining the contributions of signaling mediators such as IKKs, TAK1 or TPL2 and of complex formation with the IκB protein p105, the precursor of p50 NF-κB. Upon agonist stimulation, p105 is phosphorylated by IKK2, which causes p105 degradation and subsequent TPL2 activation and destabilization. Activation-induced p105 degradation releases Rel subunits complexed with p105. Further, a non-essential role of TPL2 in NF-κB signaling by LMP1 has been suggested.

IKK2 is critical for JNK activation by LMP1. In examining the activity of the JNK pathway in IKK2−/− cells we made a surprising observation. JNK activation by NGFR-LMP1 was almost completely blocked by the absence of IKK2, suggesting an
Fig. 1 Analysis of time-resolved signal transduction events induced by the CTAR2 domain of LMP1 through IKK2. a Schematic representation of the NGFR-LMP1 (NL) fusion constructs used in this study, compared to wildtype LMP1 (right). Y384G mutation results in a dysfunctional CTAR2 domain. Activity of NGFR-LMP1 can be triggered by NGFR-directed antibody crosslinking. b Wildtype and IKK2-deficient mouse embryonic fibroblasts (MEFs) were retrovirally transduced with NGFR-LMP1 or, in the case of wildtype MEFs, also with NGFR-LMP1(Y384G). Equivalent surface expression of the chimeras were confirmed by flow cytometry. MFI mean fluorescent intensity. c Activation of canonical NF-κB and JNK is instantly triggered at CTAR2. NGFR-LMP1 constructs were activated with NGFR antibody and a crosslinking secondary antibody for the indicated times (X-link). iκBα levels and JNK phosphorylation were detected by immunoblotting. Apparent molecular weights are given in kDa. d CTAR1-induced TRAF3 depletion remains unaffected by CTAR2 inactivation. Immunoblot analysis of detergent-soluble TRAF3 protein levels after crosslinking. e Canonical NF-κB activation by LMP1 in MEF cells depends on IKK2. f LMP1-induced p65 NF-κB translocation into the nucleus requires IKK2. Cytoplasmic and nuclear p65 NF-κB levels were analysed after antibody crosslinking. b-f The data are representative of at least two independent experiments. c-f For immunoblot quantification and statistics see Supplementary Table 3.

important and so far overlooked function of this IKK isoform in the LMP1 signaling pathway to JNK (Fig. 2a). Also the siRNA-mediated knockdown of IKK2 was sufficient to inhibit LMP1 signaling to JNK (Supplementary Fig. 1a). To further demonstrate that IKK activity is required for this pathway, the impact of IKK inhibitor VIII (AChP) on JNK activation by LMP1 was tested. Indeed, AChP reproduced the effects of IKK2 deficiency by blocking NGFR-LMP1-induced JNK1 activity (Fig. 2b). In summary, three different approaches of interference with IKK2 function verified the critical role of this IKK isoform in the JNK pathway.

LMP1 combines molecular features of TNFR and IL-1/TLR signaling, but it also uses unique mechanisms to exploit cellular signaling components, such as TRADD149. We tested, if the latter is also true for IKK2. In contrast to LMP1, TNFα was able to induce the JNK pathway in MEFs lacking IKK2, whereas both receptors relied on IKK2 to activate canonical NF-κB (Fig. 2c, compare to Fig. 1e, 2a). IL-1 activated both JNK and NF-κB in the absence of IKK2, although the response of the NF-κB pathway to IL-1 was slightly attenuated in IKK2−/− cells (Fig. 2d). This observation is in line with published data demonstrating that IKK1 can substitute for IKK2 in NF-κB signaling mediated by IL-1β. We concluded that
LMP1 activity was induced in non-targeted, wildtype (wt) MEF:NGFR-LMP1wt cells. LMP1 activity was induced in non-targeted, wildtype (wt) MEF:NGFR-LMP1wt cells by CRISPR/Cas9 technology. NGFR-LMP1 activity was induced in non-targeted cells and the JNK and canonical NF-κB were analysed. CRISPR/Cas9 knockouts were verified by immunoblotting (this Figure) and sequencing (see Supplementary Table 2).

Fig. 2 Essential functions of IKK2 and NEMO in JNK activation by LMP1. a LMP1 fails to induce JNK after the knockout of IKK2 in MEFs. LMP1 activity was induced by antibody crosslinking and JNK activation was monitored by immunoblotting. b Pharmacological inhibition of IKK activity interferes with JNK activation by LMP1. NGFR-LMP1 was induced in the presence of solvent (DMSO) or 5 μM of the IKK inhibitor VIII (ACHP). c, d IKK2 has a unique role in LMP1 signaling as compared to the TNFα and IL-1 pathways. Wildtype and IKK2−/−MEFs were stimulated with 20 ng/ml TNFα (c) or 10 ng/ml IL-1 (d) for the indicated times. e IKK1 is dispensable for JNK activation by LMP1. IKK1 was targeted by CRISPR/Cas9 in wildtype MEF:NGFR-LMP1wt and IKK2−/− MEF:NGFR-LMP1wt cells. LMP1 activity was induced in non-targeted, IKKcrKO MEF:NGFR-LMP1wt and IKKcrKO IKK2−/− MEF:NGFR-LMP1wt (clone 8) cells. Activation of JNK and canonical NF-κB was monitored. f The knockout of NEMO causes a defect in JNK activation by LMP1. NEMO was inactivated in wtMEF:NGFR-LMP1wt cells by CRISPR/Cas9 technology. NEMO-LMP1 activity was induced in non-targeted cells and the NEMOcrKO clones 2, 7, and 19. JNK and canonical NF-κB were analysed. CRISPR/Cas9 knockouts were verified by immunoblotting (this Figure) and sequencing (see Supplementary Table 2).

a-f The data are representative of at least two independent experiments. For immunoblot quantification and statistics see Supplementary Table 3.
IKK2 has an important role in LMP1 signaling to JNK, which significantly differs from its functions in TNFα and IL-1 signaling.

**LMP1 activates JNK through NEMO, while IKK1 is dispensable.** We explored the role of the remaining IKK complex components IKK1 and NEMO in JNK activation by LMP1. The siRNA-mediated knockdown of IKK1, an essential component of the noncanonical NF-κB pathway, left JNK activation by NGFR-LMP1 unaffected, whereas the downmodulation of IKK2 strongly interfered with JNK signaling (Supplementary Fig. 1a). Next, we targeted IKK1 with the help of CRISPR/Cas9 in wildtype and IKK2−/− MEFs, both expressing NGFR-LMP1. The knockout of IKK1 had no critical effect on JNK activation (Fig. 2e and Supplementary Fig. 1b). Conversely, the knockout of NEMO blocked JNK activation induced by NGFR-LMP1 (Fig. 2f). Taken together, LMP1 uses the canonical IKK complex components NEMO and IKK2 to induce JNK.

**Differential functions of TAK1 in JNK and NF-κB signaling.** To gain deeper insight into the molecular mechanism that underlies the observed functions of IKK2 in LMP1 signaling, we investigated the role of the IKK2 kinase TAK1 in this process. First, we tested if inhibition of TAK1 kinase activity by the irreversible TAK1-specific inhibitor (5Z)-7-oxozeaenol (TAK1-ih) had an effect on JNK or canonical NF-κB activity by LMP1. Although our data have shown that IKK2 is essential for both pathways, only JNK activation was down-regulated by TAK1 inhibition (Fig. 3a). This result raised the possibility that TAK1 has no function in IKK2 activation by LMP1. To address this point, we targeted TAK1 in HEK293 cells and tested the effects of TAK1 deficiency versus inhibition of its enzymatic activity on IKK2 and JNK1 activation in parallel kinase activity assays (Fig. 3b, c, respectively). Surprisingly, the knockout of TAK1 blocked both IKK2 and JNK1 activation, whereas inhibition of TAK1 kinase activity selectively interfered with JNK1 activation. Moreover, only the complete absence of TAK1 protein was sufficient to abrogate LMP1-induced phosphorylation of IKK2 at serines 177 and 181, the critical step in IKK2 activation (Fig. 3b). Supporting IKK2 autophosphorylation rather than TAK1-mediated phosphorylation as the mechanism of IKK2 activation, the IKK kinase inhibitor ACHP blocked serine 177/181 phosphorylation, whereas the TAK1 inhibitor had no effect (Fig. 3d). These data indicated that (i) the TAK1 protein, but not its kinase activity, is essential for IKK2 activation and consequently IKK2 downstream signaling to JNK and NF-κB, (ii) TAK1 does not function as an IKK2 kinase in LMP1 signaling, and (iii) IKK1 kinase activity has a role in JNK activation parallel to IKK2. The data clearly demonstrated, however, that the TAK1-IKK2 axis is critical for JNK activation by LMP1.

Next we asked about the molecular role of the TAK1 protein in IKK2 activation by LMP1. We have shown above that NEMO is a component of the LMP1 pathway to JNK. Ubiquitination of NEMO is an important step in IKK2 activation. Indeed, LMP1 induced the K63-linked ubiquitination of NEMO, which was inhibited in the absence of TAK1 (Fig. 3e). In contrast, pharmacological TAK1 kinase inhibition had little effect on NEMO ubiquitination at an inhibitor concentration that was sufficient to block JNK activation by LMP1 (Fig. 3e, compare to Fig. 3c). This result further strengthens the conclusion that TAK1 has an important function in activation of the canonical IKK complex, which is independent of IKK1 kinase activity. LMP1 forms a signaling complex incorporating IKK2 and both proteins can be precipitated together from lymphoblastoid cells (LCLs). A possible function of TAK1 in the IKK2 pathway may be to mediate complex formation, which results in IKK2 activation. HA-LMP1 interacted with Flag-IKK2 immunoprecipitated from transiently transfected HEK293 cells (Fig. 3f). Co-precipitation of both proteins was also possible vice versa (Supplementary Fig. 2a). Interaction of both proteins was lost in the absence of TAK1 in TAK1crKO cells (Fig. 3f and Supplementary Fig. 2a). Furthermore, NEMO has a function in signaling complex formation, as it facilitated the LMP1-induced interaction of TAK1 with IKK2 (Supplementary Fig. 2b). The data support a mechanism of IKK2 activation, in which TAK1 protein fosters signaling complex formation leading to NEMO ubiquitination and the subsequent activation of IKK2 through IKK2 autophosphorylation.

**LMP1 activates TPL2 through IKK2.** It was important to identify the mediator of JNK activation downstream of IKK2. TPL2 was a candidate, because it can be activated via IKK2 and its overexpression induces JNK, although a role of IKK2 upstream of TPL2 in JNK signaling has never been shown. IKK2 directly phosphorylates TPL2 at serine 400 upon LPS stimulation. The expression of IKK2 was substantially reduced in all three TPL2-depleted HEK293 cells (Fig. 4a, b). The downmodulation of IKK2 expression by LMP1, supporting the function of IKK2 as mediator of TPL2 activation, however, this may be due to TPL2 overexpression. Nevertheless, the amount of TPL2 complexed with p105 decreased from 60 min after crosslinking (Fig. 4d). Altogether this shows that LMP1 induces TPL2 phosphorylation, its release from p105 and subsequent TPL2 degradation.

To confirm whether IKK2 functions upstream of TPL2 in the LMP1 pathway, we tested if disruption of IKK2 affected TPL2 activation by LMP1. The downmodulation of IKK2 expression by siRNA and its inhibition by ACHP blocked TPL2 degradation induced by NGFR-LMP1 in MEFs (Fig. 4e, f, respectively). Also the knockout of IKK2 prevented TPL2 degradation by NGFR-LMP1, supporting the function of IKK2 as mediator of TPL2 activation in LMP1 signaling (Fig. 4g).

**TPL2 is a component of the LMP1-induced JNK pathway.** TPL2 was targeted by siRNA in MEFs to assess if TPL2 is involved in JNK activation by LMP1. Indeed, the knockdown of TPL2 impaired JNK activation by NGFR-LMP1, demonstrating an important function of TPL2 in this pathway (Fig. 5a). Treatment with the ATP-competitive TPL2 inhibitor TC-S7006 reproduced the effects obtained with TPL2 siRNA (Fig. 5b). Conversely, the downmodulation of TPL2 had no effect on LMP1-induced IkBα degradation, which argues against an essential role of this kinase in canonical NF-κB activation directly downstream of IKK2 (Fig. 5a, b). CRISPR/Cas9 technology was applied to target TPL2 in MEFs expressing NGFR-LMP1. The knockout of TPL2 also caused diminished JNK activation by LMP1, whereas IkBα degradation was not significantly affected (Fig. 5c). Next, the TPL2 gene was targeted in HEK293 cells. Three different TPL2-deficient HEK293 clones were transfected with LMP1 wildtype or the AAA/Y384G mutant together with HA-JNK1, and JNK1 activity assays were performed. JNK activation by LMP1 was substantially reduced in all three TPL2crKO clones, supporting the results previously obtained in MEFs (Supplementary Fig. 3a). Re-expression of TPL2 rescued JNK
activation by LMP1 in HEK293 cells (Supplementary Fig. 3a). Taken together, LMP1 engages TPL2 downstream of IKK2 to activate the JNK pathway.

TPL2 is dispensable for IκBα/p65 NF-κB signaling by LMP1. Neither TPL2 deficiency nor its pharmacological inhibition were sufficient to block IκBα degradation induced by NGFR-LMP1 (Fig. 5a–c). A role of TPL2 in NF-κB signaling by CTAR2 has previously been suggested, albeit via conflicting mechanisms. Therefore, we analysed the effects of TPL2 deficiency on the canonical NF-κB pathway in more detail. The knockout of TPL2 did not affect NGFR-LMP1-induced translocation of p65 NF-κB into the nucleus in MEFs (Supplementary Fig. 3b). Also serine 536 phosphorylation of nuclear p65
Fig. 3 The role of TAK1 in JNK and NF-κB signaling by LMP1. a Pharmacological TAK1 inhibition blocks JNK, but not canonical NF-κB activation by LMP1. NGFR-LMP1 was induced by antibody crosslinking in the presence of DMSO or 500 nM of the TAK1 inhibitor (S2)–7-oxozaaenol (TAK1-IH). b LMP1-induced IKK2 activity depends on the presence of TAK1 protein, but TAK1 kinase activity is dispensable. TAK1-deficient HEK293 cells (clone 3) or corresponding wildtype cells were transfected with Flag-IKK2 together with HA-LMP1, the inactive mutant HA-LMP1(AAA/Y384G), or empty vector. Where indicated, the cells were treated with 500 nM TAK1-IH for 5 h prior to cell lysis. Flag-IKK2 kinase assays were performed. IKK2 activity was measured as radioactive GST-IκB phosphorylation (topmost panel). Phosphorylation of immunoprecipitated Flag-IKK2 at serines 177/181 was detected on immunoblots. c JNK activation by LMP1 requires both TAK1 protein and its kinase activity. Experiments were essentially performed as described under c, except that HA-JNK1 was transfected and assayed using GST-c-Jun as substrate. For kinase assay quantification and statistics see Supplementary Table 3. d IKK2 activation involves IKK2 autophosphorylation. HEK293 cells were transfected as indicated and treated with DMSO, IKK inhibitor ACHP or TAK1-IH. Phosphorylation of immunoprecipitated Flag-IKK2 at serines 177/181 was detected. e LMP1 depends on TAK1 protein, but not its kinase activity, to induce K63-ubiquitination of NEMO. HEK293 and TAK1ΔK0 HEK293 cells were transfected with HA-Ubiquitin K63 and Flag-NEMO together with LMP1 wildtype or empty vector (w/o). After 24 h, cells were treated with 500 nM TAK1-IH where indicated. Flag-NEMO was immunoprecipitated (IP) using the Flag (6F7) antibody. K63-linked ubiquitination of NEMO was detected by the HA (3F10) antibody. f TAK1 mediates IKK2 interaction with the LMP1 complex. HEK293 wildtype and TAK1ΔK0 cells were transfected with Flag-IKK2 together with HA-LMP1 wildtype or AAA/D371I-386 lacking CTAR2. Flag-IKK2 was precipitated via the Flag (6F7) antibody and interacting LMP1 was detected by the HA (3F10) antibody. CRISPR/Cas9 knockouts were verified by immunoblotting (This Figure) and by sequencing (see Supplementary Table 2). a-f The data are representative of at least two independent experiments.

NF-κB remained at wildtype levels in the TPL2 knockout cells (Supplementary Fig. 3b). These results were further corroborated by the RNAi-mediated knockdown of TPL2 in MEFs, which showed no effect on p56 NF-κB translocation induced by LMP1 (Supplementary Fig. 3c). Full-length wildtype LMP1 induced the nuclear shift of p50 and p65 NF-κB in HEK293 cells, which was still the case in TPL2 knockout cells (Fig. 5d). As expected, also the CTAR1-mediated shift of noncanonical p52 and RelB remained detectable in the absence of TPL2 (Fig. 5d). Thus, TPL2 does not significantly contribute to the activation of the canonical NF-κB pathway by LMP1 at the level or upstream of NF-κB translocation.
IKK2-TPL2 signal JNK activation by LMP1 in human B cells. Human B cells are the main target cells of EBV. It was therefore important to explore if this novel mechanism of JNK activation by LMP1 via the IKK2-TPL2 axis is also operative in B cells. Moreover, it was of interest to investigate if the LMP1 pathway to JNK differs from CD40 signaling. To this end, human BL41 Burkitt’s lymphoma B cells expressing NGFR-LMP1 were either crosslinked with antibodies to induce LMP1 activity or stimulated with CD40 ligand in the presence or absence of inhibitors (Fig. 6a–d and Supplementary Fig. 4). LMP1 executes a similar molecular program to activate the JNK pathway in B cells as identified above in other cell types. LMP1 relied on IKK2 and TPL2 to activate JNK in BL41 cells (Fig. 6a, c, respectively). In contrast to LMP1, CD40 signaling to JNK was independent of IKK2 and TPL2 (Fig. 6b, d, respectively). The latter observation is in line with previously published data excluding a role for TPL2 in JNK signaling by CD4040. The same authors showed that CD40 activates the ERK pathway via TPL2 in primary murine B cells40. Extending this, we observed that ERK activation by both CD40 and LMP1 involves IKK2 and TPL2 in BL41 cells (Fig. 6a–d). Finally, we addressed the role of TAK1 in CD40 and LMP1 signaling. TAK1 kinase activity was required for JNK, but not canonical NF-kB, activation by LMP1 in B cells, reflecting our previous observations in non-B cells (Supplementary Fig. 4a). In contrast, CD40 was dependent on the enzymatic activity of TAK1 to induce both NF-kB and JNK (Supplementary Fig. 4b). In summary, the mechanism of JNK activation by LMP1 is similar between B cells and non-B cells. Moreover, LMP1 and CD40 signaling differ with respect to the molecular functions of TAK1, IKK2, and TPL2.

To confirm the existence of the LMP1-induced IKK2-TPL2-JNK pathway in EBV-transformed B cells, the natural context of LMP1 function as an oncogene, we freshly infected primary human B cells with recombinant EBV, in which the LMP1 gene had been replaced by the NGFR-LMP1 chimera53. The resulting LCL-NGFR-LMP1.6 lymphoblastoid cells fully depend on LMP1 signals to proliferate (Fig. 6e). NGFR-LMP1 caused a robust upregulation of the JNK and canonical NF-kB pathways about 30 min after antibody crosslinking (Fig. 6f). As in non B cells and BL41 cells, LMP1 signaling to JNK was fully dependent

**Fig. 5 TPL2 mediates JNK activation by LMP1, but it is dispensable for NF-kB induction.** a The knockdown of TPL2 interferes with JNK activation by LMP1. Wildtype MEF-NGFR-LMP1wt cells were transfected twice with siRNA targeting TPL2 (sTPL2) or non-targeting control siRNA (siCTRL) prior to NGFR-LMP1 activation. b Pharmacological inhibition of TPL2 attenuates JNK activation by LMP1. Detection of JNK and NF-kB activation were analysed.

---

**ARTICLE**

**NATURE COMMUNICATIONS**

**https://doi.org/10.1038/s41467-020-14502-x**

**www.nature.com/naturecommunications**
on IKK2 in these LCLs (Fig. 6f). Also IκB degradation induced by NGFR-LMP1 was blocked by ACHP. TPL2 inhibition caused a marked decrease in JNK activation, whereas induction of canonical NF-κB was not affected. IKK2 and TPL2 are, thus, mediators of JNK activation by LMP1 in EBV-transformed B cells, which depend on LMP1 signals.

LCL survival is mediated by the IKK2-TPL2 pathway. As the next step we evaluated the significance of the LMP1-induced IKK2-TPL2 pathway in cell transformation by EBV. LMP1 drives cell proliferation of LCLs and simultaneously protects cells from apoptosis by induction of NF-κB and JNK1. Inhibition of the canonical NF-κB pathway by expression of a dominant-negative
IkBa caused cell death in LCLs\textsuperscript{20,54}. Consistent with these data, ACHP treatment strongly interfered with proliferation of LCLs and LCL.NGR-LMP1.6 cells (Supplementary Fig. 5a, b, respectively).

However, as demonstrated above, IKK2 inhibition does not discriminate between NF-kB and JNK downstream signaling. To be more specific for the IKK2-TPL2 axis, we tested the effects of TPL2 inhibition on LCLs. Steady-state phosphorylation of the direct JNK target c-Jun, indicating cellular JNK activity levels, was significantly reduced already 3 h after incubation of LCL721 cells with TPL2 inhibitor (Fig. 7a). This result further confirmed that the JNK pathway is dependent on TPL2 in LCLs. Of note, JNK activity in LCLs is mediated by LMP1\textsuperscript{15,55} (see Fig. 6). In contrast, IkBa levels remained unaffected by TPL2 inhibition, whereas ACHP blocked canonical NF-kB and JNK in LCL721 cells (Fig. 7a). Increased apoptosis was not detected at 3–6 h after incubation with TPL2-IH, excluding cell death as an explanation for the observed effects on the JNK pathway. TPL2 inhibition efficiently retarded proliferation of the two lymphoblastoid cell lines LCL721 and LCL IC3 as well as of LCL.NGR-LMP1.6 cells (Fig. 7b and Supplementary Fig. 5b, respectively). TPL2-IH elicited a strong apoptotic response in LCL721 and LCL IC3 cells after 24 and 48 h of TPL2 inhibition, demonstrating that TPL2 is required for LCL survival (Fig. 7c). This effect was specific for EBV/LMP1-transformed cells, because EBV-negative BL41 cells remained unaffected by TPL2-IH treatment (Fig. 7d).

In accordance with the pro-survival function of TPL2 in lymphoblastoid cells, TPL2-IH caused an upregulation of caspase 3 activity in both LCLs, which was comparable to the effects elicited by the apoptosis inducer staurosporin (Fig. 7e).

LMP1-positive PTLD and carcinoma depend on IKK2-TPL2-JNK. PTLD induced by EBV constitutes a severe complication in transplant recipients. To test if the LMP1-IKK2-TPL2-JNK pathway is also effective in PTLD, primary tumor cells were established in culture from tumor biopsies of two PTLD patients, resulting in PTLD099 and PTLD880 cells. LCL877 was generated by parallel in vitro infection of primary B-cells of patient 880 with B95.8 EBV and served as LCL control for PTLD880. The EBV-encoded LMP1 genes expressed in PTLD099 and PTLD880 were sequenced. The signaling domains of the two tumor-derived LMP1 variants exhibit sequence alterations when compared to B95.8 prototyoe LMP1 and when compared to each other (Supplementary Fig. 6). For instance, only LMP1 of PTLD880 carries an insertion of three 16-aa repeats. Moreover, both PTLD variants of LMP1 carry point mutations at previously described mutational hotspots (Supplementary Fig. 6 and references therein). ACHP caused a marked reduction of c-Jun phosphorylation levels in both PTLD samples as well as in the corresponding LCL877, demonstrating a downregulation of JNK activity by IKK2 inhibition in PTLD (Fig. 8a). ACHP also blocked the canonical NF-kB pathway in these tumor cells as indicated by IkBa stabilization (Fig. 8a). Notably, TPL2 inhibition interfered with JNK activity in PTLD cells, too, whereas IkBa remained unaffected (Fig. 8b). These results confirmed the relevance of the IKK2-TPL2 pathway for JNK activation even in primary PTLD tumor cells. Strikingly, this pathway is required for survival of PTLD as pharmacological IKK2 and TPL2 inhibition very efficiently blocked proliferation of PTLD cells and the corresponding LCL (Fig. 8c, d, respectively).

LMP1 is also important for nasopharyngeal carcinoma development in humans and it has oncosuppressive potential in rodent fibroblasts. Expressed in the epidermis of mice, LMP1 induces hyperplasia\textsuperscript{9}. We therefore tested if TPL2 inhibition also affects the survival of LMP1-positive murine carcinoma cells, which had been established from mice expressing an LMP1 transgene (LMP1tg) in the epidermis\textsuperscript{8,55}. The LMP1tg-positive carcinoma line 53.234a largely depends on LMP1 for efficient proliferation and clonogenicity, whereas the LMP1tg-negative line 53.217 is independent of LMP1\textsuperscript{55}. Indeed, TPL2 inhibition induced apoptosis in the LMP1tg-dependent 53.234a carcinoma cells, whereas 53.217 cells remained unaffected (Supplementary Fig. 7). Taken together, the IKK2-TPL2 pathway is an important mediator of JNK activation and survival of LMP1-transformed cells, observed in a variety of cell and tumor types.

Discussion

Here we describe an important role of IKK2 and its interactor NEMO in the activation of the JNK pathway, which is a new twist in the molecular functions and biology of the canonical IKK complex. The IKK2-dependent JNK pathway is a readout of the EBV oncoprotein LMP1 in the context of cell transformation and survival of tumor cells. LMP1 is among the most effective JNK inducers, which requires the MAPK to exert its proliferative and anti-apoptotic activity by during B-cell growth transformation and tumor development by EBV\textsuperscript{15,21}. Several functions in tumorgenesis beyond NF-kB activation have been ascribed to IKK2, including the regulation of p53 stability by direct phosphorylation\textsuperscript{56}. Our findings extend the spectrum of IKK2 to a role in oncogenic JNK signaling by engaging TPL2 as downstream mediator. TPL2 has previously been implicated in cell transformation and cancer\textsuperscript{56}. However, a critical role of TPL2 in JNK signaling downstream of IKK2 has not been described. The IKK2-TPL2-JNK axis is thus a new signaling module regulating cell transformation.

Our results support a model of CTAR2 signaling to JNK and NF-kB, which involves IKK2 as a key player for activation of both pathways (Fig. 9). The CTAR2 signalosome includes TRAF6 as critical component proximal to the receptor\textsuperscript{17,18}. TRADD, TAK1, TABs, TNIK, and the canonical IKK complex are further recruits\textsuperscript{14,19,25,46,49}. We show here that TAK1 mediates IKK complex interaction with LMP1 and facilitates the ubiquitination of NEMO independent of its kinase activity. Although the exact mechanism whereby NEMO regulates IKK2 is still unknown, NEMO ubiquitination is an important step preceding IKK2 activation\textsuperscript{28,34,56}. IKK2 requires the phosphorylation of serine residues 177 and 181 within its activation loop to be active\textsuperscript{28,34,56}. Direct phosphorylation of IKK2 by the IKK2 kinase TAK1 is the most straightforward mechanism of IKK2 activation, as it has been demonstrated for TNF\alpha and IL-1 signaling\textsuperscript{32,33}. The kinase activity of TAK1, however, is not required for IKK2 induction by LMP1. Also a potential role of the alternative IKK2 kinase MEKK1 can be excluded, because LMP1 activates IKK2 in MEKK1 knockout cells\textsuperscript{19}. How is IKK2 phosphorylation then achieved in LMP1 signaling? The requirement of TAK1 for IKK2 activation is not universal\textsuperscript{36,57}. A discussed alternative scenario of IKK2 activation independent of an IKK2 kinase involves IKK2 binding to ubiquitinated NEMO. This interaction may then lead to conformational changes in IKK2, which facilitate the herein observed autophosphorylation of IKK2 after LMP1 activation\textsuperscript{28,34}. Despite being dispensable for the IKK2-TPL2 axis, TAK1 kinase activity is obligatory for JNK activation by LMP1. TAK1 kinase must act towards JNK in a second pathway parallel to IKK2. Both TPL2 and TAK1 activate MAPK kinases (M KKs) that are known to regulate JNK activity\textsuperscript{31,58}. Likely, TPL2 and TAK1 converge at the level of MKK4 and 7, which induce JNK synergistically\textsuperscript{59}. In summary, our findings define novel functions of TAK1, NEMO, IKK2, and TPL2 in JNK signaling. They further resolve inconsistent conclusions in the literature regarding the role of TAK1 in LMP1 activation of JNK and NF-kB, which...
resulted from different methods of interference with TAK1 function.\textsuperscript{19,26,46,47}

Although TPL2 is mainly involved in ERK activation by pro-inflammatory agonists, it can contribute to optimal JNK induction by TNFR1 in MEFs.\textsuperscript{41} However, TNFRI activates JNK independently of IKK2, whereas JNK signaling by LMP1 relies on the canonical IKK complex. How can these differences in downstream signaling between the two receptors be explained?
TNFR1 requires TRAF2 and RIP1 to activate TPL2 and JNK. In contrast, LMP1-CTAR2 signaling to JNK fully depends on TRAF6, whereas TRAF2 is largely dispensable. CD40, which activates JNK independently of IKK2 in our experiments, also relies on TRAF2 for JNK signaling. It is conceivable that the signaling complexes of LMP1, TNFR1 and CD40 determine different ubiquitination processes via engagement of different TRAF ubiquitin ligases in combination with specific scaffolding proteins such as TRADD or TNIK. In line with this hypothesis, LMP1 was shown to activate IKK2 independently of the NEMO zinc finger, which binds polyubiquitin chains and is required for IKK2 activation by TNFα and CD40.

Fig. 8 The IKK2-TPL2-JNK pathway mediates proliferation of LMP1-expressing PTLD tumor cells. a IKK inhibition blocks the JNK and canonical NF-κB pathways in PTLD. PTLD099 and PTLD880 cells isolated from two different PTLD tumor biopsies and LCL877 corresponding to PTLD880 were incubated with DMSO or 10 µM of ACHP for 3 h. Chemiluminescence signals of immunoblots using the indicated antibodies were quantified directly. Paired signals standardized to total protein levels of three biological replicates are shown. Chemiluminescence values (y-axes) are relative and do not allow for direct comparison between graphs. b TPL2 mediates JNK, but not canonical NF-κB, activity in PTLD cells. The experiment was performed as described in a, except that 10 µM of TPL2 inhibitor TC-S7006 was used. Paired signals standardized to total protein levels of three (PTLD099, LCL877) or four (PTLD880) biological replicates are shown. c ACHP blocks proliferation of PTLD tumor cells. Cells were incubated with or without DMSO, or in the presence of 10 µM of ACHP. At the indicated times, MTT assays were performed. d TPL2 is required for PTLD proliferation. MTT assays in the presence of 10 µM of TPL2-IH. The data are mean values ± SD of three biological replicates. a–d Statistical analysis was performed with the ratio paired T-test (two-tailed). Statistical analysis was performed with two-way ANOVA at alpha 0.05. a–d p-values: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, n.s. not significant.
results now demonstrate that IKK inhibition combines deleterious effects upon NF-κB signaling with the blockade of the JNK pathway, which is also important for LCL proliferation.\textsuperscript{34} IKK2 could be a potential target for the treatment of EBV-induced malignancies. However, the NF-κB pathway is not only a weak point of EBV-transformed tumor cells and many lymphomas, it is also an important system in immune homeostasis.\textsuperscript{35} Systemic IKK inhibition might therefore cause many unwanted side effects. Here we show that TPL2 inhibition interferes with survival of LCLs, PTLD tumor cells and LMP1-dependent carcinoma cells. TPL2 has previously been identified as target for anti-inflammatory drugs, because it is selectively activated by inflammatory stimuli.\textsuperscript{36} Moreover, TPL2-deficient mice are viable, develop normally and have life spans comparable to wildtype littermates when kept under germ-free conditions.\textsuperscript{37} Drugs targeting TPL2 should therefore have fewer systemic side effects than IKK inhibitors. On the basis of our results that TPL2 mediates oncogenic JNK signaling by LMP1 and cell survival of EBV-transformed cells, TPL2 should be considered as an attractive target for new drugs or the repurposing of existing inhibitors against EBV-induced malignancies such as PTLD in the future.

**Methods**

**Cell lines and cell culture.** HEK293 cells were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ). IKK2\textsubscript{2/−/−} MEFs (provided by M. Schmidt-Supprian) were established from IKK2 knock-out mice.\textsuperscript{48} The lymphoblastoid cell line LCL 1C3 (provided by J. Mautner) was generated by infection of primary human B cells with B95.8 EBV. BL41-NGFR-LMP1wt cells (provided by J. Mautner), EBV-negative BL41 Burkitt lymphoma cells and LCL721 have been described and were taken from own laboratory stocks.\textsuperscript{63-65} The LMP1 transgene (LMP1\textsuperscript{tg})-positive carcinoma cell line S3.244a and corresponding LMP1-negative S3.217 carcinoma cells were established from LMP1\textsuperscript{tg} mice or LMP1\textsuperscript{−/−} controls, respectively and have been described.\textsuperscript{65} HEK293-NGFR-LMP1 cells were generated by PolyFect (Qiagen) transfection of HEK293 cells with pSV-NGFR-LMP1 in combination with a hygromycin-resistance vector and subsequent hygromycin selection. All mouse embryonic fibroblasts, derivatives thereof, and murine carcinoma cells were cultured at 37°C and 5% CO\textsubscript{2} in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS) and penicillin/streptomycin. HEK293 cells, HEK293 derivatives, and B cells were kept in RPMI-1640 medium plus 10% FCS and penicillin/streptomycin. BL41: NGFR-LMP1wt cells were grown in the presence of 1 μg/ml puromycin and HEK293-NGFR-LMP1 cells in the presence of 100 μg/ml hygromycin. Cells were stimulated with the indicated concentrations of recombinant human TNFα (Applichem), murine interleukin-1α (Tebu-Bio) or human recombinant soluble CD40 ligand (Source BioScience). The inhibitors TC-8706 (TPEL-1H, Biotechne), (5Z)-7-oxozeaenol (TAK1-IH, Millipore), and ACHP (IKK Inhibitor VIII, Millipore) were dissolved in DMSO and used as indicated.

**Establishment of PTLD cells and LCLs.** PTLD099 and PTLD880 cells were established from anonymised tumor biopsies of two adult patients with cytopathologically confirmed EBV-positive PTLD after allogeneic hematopoietic stem cell transplantation. Tissue was disintegrated with scalpels in PBS and passed through a 100 μm Nylon cell strainer. Cells were washed and cultured in RPMI medium supplemented with 10% FCS and penicillin/streptomycin in the presence of 1 μg/ml of cyclosorine A (96-well plate, 5 × 10\textsuperscript{4} cells per well in a volume of 200 μl). Half of the culture supernatant was replaced every 5–7 days by fresh medium (containing cyclosporine A for the first 4 weeks). When global cell proliferation was observed, cultures were gradually expanded until stable cell proliferation in a volume of 10 ml was achieved. At this point (day 90 for PTLD099, day 62 for PTLD880), cells were cryoconserved or further used in experiments. The LMP1 genes of PTLD099 and PTLD880 were amplified by PCR and the signaling domains were sequenced. Primer sequences are given in Supplementary Table 1. Lymphoblastoid cell line LCL1C3 was derived from primary cells of the same PTLD biopsy that gave rise to PTLD880, but was infected with EBV laboratory strain B95.8. Cells obtained as described above were plated in medium with cyclosporine A containing 10 μg/ml of filter (0.7 μm) supernatant from EBV-producing cell line B95.8. Cells were further cultured and expanded as described above for PTLD cell lines.

LCL-NGFR-LMP1.6 cells were established by infection and conditional transformation of peripheral blood B cells of an adult EBV-negative donor with recombinant maxi-EBV 2264.19, carrying NGFR-LMP1 instead of wildtype LMP1.\textsuperscript{42} Initial outgrowth of infected B cells was supported by plating PBMCs on top of an adherent layer of irradiated L12 mouse fibroblasts expressing human CD40L.\textsuperscript{68} At day 14, the cells were removed from the feeder layer and then continuously cultured in the presence of crosslinking antibodies (see NGFR-
LMP1 crosslinking) to maintain LMP1 signals and proliferation. After 8 weeks, the culture expanded to approximately 10^6 cells and was used for experiments.

**Ethics.** We complied with all relevant ethical regulations for work with human participants. Anonymous human PTLD biopsies and blood from a healthy human donor were obtained with informed consent as approved by the Institutional Review Board (Ethics Commission of the Faculty of Medicine of the Ludwig-Maximilians-University Munich, project no. 071–06–075–06).

**Plasmids.** The plasmids pCMV-HA-LMP1 wildtype, pCMV-HA-LMP1(ΔAS71–386) harboring a P204xQxT to AxxA mutation within CTAR1 and lacking the 16 C-terminal amino acids of CTAR2, pCMV-HA-LMP1(ΔAS384–Y384), pSV-LMP1, pSV-LMP1(ΔAS384–Y384), pcDNA3-Flag-IKK2, and pRK5-HA-INK1 have been described. The vector pSV-NF-κB-LMP1 encoding a fusion protein of aa 1–279 of human low affinity p75 NF-κR and aa 196–386 of LMP1 has been described. Retroviral transduction

**Retroviral transduction.** NGFR-LMP1 wildtype and NGFR-LMP1(ΔAS384–Y384) were silenced from pSV-NF-κB-LMP1 into the retroviral vector pSP91-IRE5-GFP-WPRE (provided by C. Baum) . For virus production, phoenix-gp cells were infected with pEcoEnv expressing ecotropic Env protein as described. MEFs were infected with pCMV-HA-LMP1 wildtype, pCMV-HA-LMP1(AAA/Y384G), pSV-LMP1(ΔAS384–Y384), pcDNA3-Flag-IKK2, and pRK5-HA-INK1 have been described. Immunoblotting and quantification

**Immunoblotting and quantification.** For immunoblotting, proteins were separated on 12.5% SDS-PAA gels, and blotted to nitrocellulose membrane (Bio-Rad). Immunoblots were visualized using a secondary antibody coupled to horseradish peroxidase and ECL reagent. For quantification of ECL signals captured on X-ray films, signals were analysed by densitometry using the ImageJ software. Results are shown in Supplementary Table 3. ECL Chemiluminescence Summary of endoproteinase, trypsinogen, b were detected directly by the Vilber Fusion FX6 Edge imager and analysed by the Vilber Bio-ID software. Signals were standardized to total protein levels. Statistical analysis was performed using the GraphPad Prism 6 software (see Statistical analysis). For coinmunoprecipitations, the cells were transfected in 15 cm dishes with the indicated plasmids and PolyFect transfection reagent. Twenty-four hours after transfection, protein extracts were analysed by immunoblotting. For the latter, samples were proteinase K-treated before lysis and the cell lysates were analysed by densitometry using the ImageJ software. Results are shown in Supplementary Table 4.

**Nuclear shift assay.** HEK293 cells and MEFs were transfected in 10 cm dishes with the indicated expression vectors, pEFAC-3xFlag-IKKWyt (NEMO) and pRK5-HA-ubiquitin K63 (all lysines mutated to arginines except of K63) was obtained from Addgene and has been described. Immunocomplex kinase assays and quantification

**Immunocomplex kinase assays and quantification.** HEK293 cells were transfected in six-well plates with 1 µg each of the indicated constructs and 1 µg of plasmids pCMV-HA-LMP1(AAA/Y384G)+Flag-IKK2 or pCMV-HA-LMP1 wildtype+Flag-IKK2 using FuGENE HD transfection reagent. For TPL2 rescues, 0.1 µg of TPL2-myc expression vector was co-transfected in Supplementary Fig. 3a. Twenty-four hours after transfection, cells were lysed in NP-40 lysis buffer and HA-jNK1 or Flag-IKK2 were immunoprecipitated via their epitope tags. Beads were washed twice with NP-40 lysis buffer and twice with reaction buffer (20 mM Tris-HCL pH 7.4, 2 mM NaCl, 10 mM MgCl2, 2 µM ATP). In vitro kinase reactions were performed in the presence of 10 µCi of [γ-32P]-ATP and 1 µg of recombinant GST-c-Jun or GST-IκBα, respectively, for 25 min at 27°C. Samples were subjected to SDS-PAGE and autoradiography. Radioactive signals were quantified using the Typhoon FLA-7000 phosphorimager (GE Healthcare) and normalized to the amounts of immunoprecipitated kinase. Quantitative kinase assay results are shown in Supplementary Table 4.

**Cell proliferation and apoptosis.** Metabolic MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) conversion by viable cells was used to monitor cell proliferation. Flow cytometric analysis of PI and annexin V-Cy5 staining was performed with the FACS CantoII protocol. Flow cytometric analysis of PI and annexin V-Cy5 staining was performed with the FACS Calibur flow cytometer (Becton Dickinson). Data processing was performed with FlowJo software.

**NEMO ubiquitination.** HEK293 cells were transfected in 10 cm dishes with the indicated expression vectors, pEFAC-3xFlag-IKKWyt (NEMO) and pRK5-HA-ubiquitin K63. Cells were lysed 24 h post transfection in NP-40 lysis buffer supplemented with 10 mM N-ethylmaleimide. Flag-NEMO was immunoprecipitated via its Flag-tag and K63 linked ubiquitination was analysed by immunoblotting with HA primary antibody recognizing HA-Ub K63 modification of Flag-NEMO. Immunoblotting and quantification, immunoprecipitation

**Immunoblotting and quantification, immunoprecipitation.** For immunoblotting and immunoprecipitation experiments cells were lysed on ice in NP-40 lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.1% NP-40) supplemented with phosphatase inhibitors (0.5 mM sodium orthovanadate, 0.5 mM NaF, 0.5 mM sodium molybdate, 0.5 mM sodium pyrophosphate, 50 mM β-glycerophosphate) and complete protease inhibitor cocktails (Roche). Lysates were cleared by centrifugation, separated by SDS-PAGE on 12.5% SDS-PAA gels, and blotted to nitrocellulose membrane (Bio-Rad). Immunoblots were visualized using a secondary antibody coupled to horseradish peroxidase and ECL reagent. For quantification of ECL signals captured on X-ray films, signals were analysed by densitometry using the ImageJ software. Results are shown in Supplementary Table 3. ECL Chemiluminescence Summary of endoproteinase, trypsinogen, b were detected directly by the Vilber Fusion FX6 Edge imager and analysed by the Vilber Bio-ID software. Signals were standardized to total protein levels. Statistical analysis was performed using the GraphPad Prism 6 software (see Statistical analysis). For coinmunoprecipitations, the cells were transfected in 15 cm dishes with the indicated plasmids and PolyFect transfection reagent. Twenty-four hours after transfection, protein extracts were analysed by immunoblotting. For the latter, samples were proteinase K-treated before lysis and the cell lysates were analysed by densitometry using the ImageJ software. Results are shown in Supplementary Table 4.

**Caspase activity assay.** Caspase 3 activity was monitored using the Caspase Colorimetric Substrate Set Kit (K#132, Biovision) according to the manufacturer’s protocol. Cells were treated as indicated with 10µM TC-S7006 for 24h before cell lysis.
Caspase 3 substrate was added to the lysates and incubated for 2 h at 37 °C. Caspase 3 activity was measured as colorimetric substrate conversion at 405 nm wavelength.

**Statistical analysis.** Statistics was performed using Graphpad Prism 6 software. T-test (two-tailed) was performed for unpaired samples (Supplementary Tables 3, 4). Two-way ANOVA analysis was performed for grouped samples. Ratio paired T-test (two-tailed) was applied for paired samples (Figs. 7a, 8a, b).

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability** LMP1 sequencing data have been deposited in GenBank under the accession codes MN244676 for PTLD999 and MN244677 for PTLD880. Original uncropped scans of blots and other important original data are supplied in the Source Data file.

Received: 12 June 2018; Accepted: 10 December 2019; Published online: 04 February 2020

**References**

1. Kieser, A. & Sterz, K. R. The latent membrane protein 1 (LMP1). *Curr. Top. Microbiol. Immunol.* **391**, 119–149 (2015).

2. Young, L. S., Yap, L. F. & Murray, P. G. Epstein-Barr virus: more than 50 years old and still providing surprises. *Nat. Rev. Cancer* **16**, 789–802 (2016).

3. Tsao, S. W., Tsang, C. M., To, K. F. & Lo, K. W. The role of Epstein-Barr virus in epithelial malignancies. *J. Pathol.* **235**, 323–333 (2015).

4. Kieff, E., Kaiser, C. & Hammerschmidt, W. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. *EMBO J.* **16**, 6478–6485 (1997).

5. Kieser, A., Kaiser, C. & Hammerschmidt, W. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. *EMBO J.* **16**, 6478–6485 (1997).

6. Izumi, K. M. & Kieff, E. D. The Epstein-Barr virus oncogene product latent membrane protein 1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. *EMBO J.* **16**, 6478–6485 (1997).

7. Kieff, E., Kaiser, C. & Hammerschmidt, W. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. *EMBO J.* **16**, 6478–6485 (1997).

8. Luftig, M. et al. Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF2. *Proc. Natl Acad. Sci. USA* **100**, 15395–15400 (2003).

9. Wu, L., Nakano, H. & Wu, Z. The C-terminal activating region 2 of the Epstein-Barr virus-encoded latent membrane protein 1 activates NF-kappaB through TRAF6 and TAK1. *J. Biol. Chem.* **281**, 2162–2169 (2006).

10. Cahir-McFarland, E., Davidson, D. M., Schauer, S. L., Duong, J. & Kieff, E. NF-kappaB inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. *Proc. Natl Acad. Sci. USA* **97**, 6055–6060 (2000).

11. Kutz, H., Reisbach, G., Schultheiss, U. & Kieff, A. The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein-Barr virus. *Virology* **371**, 246–256 (2008).

12. Greenfield, H. et al. TRAF6 coordinates polyubiquitin signaling to enhance Epstein-Barr virus LMP1-mediated growth and survival pathway activation. *PLoS Pathog.* **11**, e1004890 (2015).

13. Wang, L. et al. The linear ubiquitin assembly complex modulates latent membrane protein 1 activation of NF-kappaB and JNK signaling in B-cells by the EBV oncoprotein LMP1 and the CD40 receptor. *PLoS Biol.* **10**, e1001376 (2012).

14. Gewurz, B. E. et al. Genome-wide siRNA screen for mediators of NF-kappaB activation. *Proc. Natl Acad. Sci. USA* **109**, 2467–2472 (2012).

15. Ben-Neriah, Y. & Karin, M. Inflammation meets cancer, with NF-kappaB as the matchmaker. *Nat. Immunol.* **12**, 715–723 (2011).

16. Hinz, M. & Scheider, C. The IkappaB kinase complex in NF-kappaB regulation and beyond. *EMBO Rep.* **15**, 46–61 (2014).

17. Krapfmann, D. & Vincendeau, M. Mechanisms of NF-kappaB deregulation in lymphoid malignancies. *Semin. Cancer Biol.* **19**, 3–14 (2016).

18. Vallabhapurapu, S. & Karin, M. Regulation and function of NF-kappaB transcription factors in the immune system. *Annu. Rev. Immunol.* **27**, 693–733 (2009).

19. Xu, G. et al. Crystal structure of inhibitor of kappaB kinase beta. *Nature* **472**, 325–330 (2011).

20. Wang, C. et al. TAK1 is a ubiquitin-dependent kinase of MKK and I KK. *Nature* **412**, 346–351 (2001).

21. Zhang, J., Clark, K., Lawrence, T., Peggie, M. W. & Cohen, P. An unexpected twist to the activation of IKKbeta: TAK1 primes IKKbeta for activation by autophosphorylation. *Biochem. J.* **461**, 531–537 (2014).

22. Israel, A. The IKK complex, a central regulator of NF-kappaB activation. *Cold Spring Harb. Perspect. Biol.* **2**, a001580 (2010).

23. Boehm, D., Gewurz, B. E., Kieff, E. & Cahir-McFarland, E. Epstein-Barr latent membrane protein 1 transformation site 2 activates NF-kappaB in the absence of NF-kappaB essential modifier residues 133-224 or 373-419. *Proc. Natl Acad. Sci. USA* **107**, 18103–18108 (2010).

24. Youngoukakali, M., Kanelis, D. C., Gkouskou, K. & Eilopoulos, A. G. Tp2 kinase signal transduction in inflammation and cancer. *Cancer Lett.* **304**, 80–89 (2011).

25. Gantke, T., Sriskantharajah, S., Sadowski, M. & Ley, S. C. IkappaB kinase regulation of the TPL-2/ERK MAPK pathway. *Immunol. Rev.* **246**, 168–182 (2011).

26. Patrhot, C., Makris, A., Chernoff, J. & Tsichlis, P. N. Tp2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase. *Proc. Natl Acad. Sci. USA* **91**, 9755–9759 (1994).

27. Dannniri, C. D. et al. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tp2/ERK-dependent pathway. *Cell* **103**, 1071–1083 (2000).

28. Eilopoulos, A. G., Wang, C. C., Dumniru, C. D. & Tsichlis, P. N. Tp2 transduces CD40 and TNF signals that activate ERK and regulates EG induction by CD40. *EMBO J.* **22**, 3855–3864 (2003).

29. Das, S. et al. Tp2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. *J. Biol. Chem.* **280**, 23748–23757 (2005).

30. Pattison, M. J. et al. TLR and TNF-R1 activation of the MKK3/MKKe6-p38alpha axis in macrophages is mediated by TPL-2 kinase. *Biochem. J.* **473**, 2845–2861 (2016).

31. Seiger, K. et al. The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation. *Sci. Signal.* **10**, eaax473 (2017).

32. Gkitzitiamanaki, K. et al. TPL2 kinase is a suppressor of lung carcinogenesis. *Proc. Natl Acad. Sci. USA* **110**, E1470–E1479 (2013).

33. Eilopoulos, A. G. et al. The oncopgenic protein kinase Tp2/cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-kappaB signaling downstream of TRAF2. *J. Virol.* **76**, 4567–4579 (2002).

34. Umura, N. et al. TAK1 is a component of the Epstein-Barr virus LMP1 complex and is essential for activation of JNK but not of NF-kappaB. *J. Biol. Chem.* **281**, 7863–7872 (2006).

35. Arcipowski, K. M. & Bishop, G. A. Roles of the kinase TAK1 in TRAF6-dependent signaling by CD40 and its oncogenic viral mimic, LMP1. *PLoS ONE* **7**, e42478 (2012).

36. Gires, O. et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. *EMBO J.* **16**, 6131–6140 (1997).
49. Schneider, F. et al. The viral oncoprotein LMP1 exploits TRADD for signaling by masking its apoptotic activity. *PLoS Biol.* 6, e8 (2008).

50. Solt, L. A., Madge, L. A., Orange, J. S. & May, M. J. Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta. *J. Biol. Chem.* 282, 8724–8733 (2007).

51. Salmeron, A. et al. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. *EMBO J.* 15, 817–826 (1996).

52. Roget, K. et al. Ikkappa kinase 2 regulates TPL-2 activation of extracellular signal-regulated kinases 1 and 2 by direct phosphorylation of TPL-2 serine 400. *Mol. Cell. Biol.* 32, 4684–4690 (2012).

53. Dirmeyer, U. et al. Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis. *Onkogene* 24, 171–177 (2005).

54. Cahir-McFarland, E. D. et al. Role of NF-kappaB in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. *J. Virol.* 78, 4108–4119 (2004).

55. Hannigan, A. & Wilson, J. B. Evaluation of LMP1 of Epstein-Barr virus as a therapeutic target by its inhibition. *Mol. Cancer* 9, 184 (2010).

56. Liu, F., Xia, Y., Parker, A. S. & Verma, I. M. IKK biology. *Immunol. Rev.* 246, 239–253 (2012).

57. Chen, Z. J. Ubiquitination in signaling to and activation of IKK. *Cell Signal.* 24, 95–106 (2012).

58. Hirata, Y., Takahashi, M., Morishita, T., Noguchi, T. & Matsuawa, A. Post-Translational Modifications of the TAK1-TAB Complex. *Int. J. Mol. Sci.* 18, E205 (2017).

59. Fleming, Y. et al. Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. *Biochem. J.* 352(Pt 1), 145–154 (2000).

60. Hoetger, B. S., Hashinasto, S. A., Rowland, S. L. & Bishop, G. A. Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. *J. Biol. Chem.* 278, 45382–45390 (2003).

61. Cordier, F. et al. The zinc finger of NEMO is a functional ubiquitin-binding domain. *J. Biol. Chem.* 284, 2902–2907 (2009).

62. Chan, H. & Reed, J. C. TRAF-dependent association of protein kinase Tpl2/COTI (MAP3K8) with CD40. *Biochem. Biophys. Res. Commun.* 328, 198–205 (2005).

63. Cohen, P. Targeting protein kinases for the development of anti-inflammatory drugs. *Curr. Opin. Cell Biol.* 21, 317–324 (2009).

64. Schmidt-Supprian, M. et al. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. *Mol. Cell 5*, 981–992 (2000).

65. Kavathas, P., Bach, F. H. & DeMars, R. Gamma ray-induced loss of expression of HLA and glyoxalase I alleles in lymphoblastoid cells. *Proc. Natl Acad. Sci. USA* 77, 4251–4255 (1980).

66. Marchini, A., Longnecker, R. & Kieff, E. Epstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants. *J. Virol.* 66, 4972–4981 (1992).

67. Nimmerjahn, F. et al. Active NF-kappaB signalling is a prerequisite for influenza virus infection. *J. Gen. Virol.* 85, 2347–2356 (2004).

68. Rancan, C., Schirrmann, L., Huls, C., Zeidler, R. & Moosmann, A. Latent membrane protein LMP2A impairs recognition of EBV-infected cells by CD8+ T cells. *PLoS Pathog.* 11, e1004906 (2015).

69. Ceci, J. D. et al. Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. *Genes Dev.* 11, 688–700 (1997).

70. Heissmeyer, V., Krappmann, D., Walczyn, F. G. & Scheidereit, C. NF-kappaB latency III-infected cells. *J. Virol.* 78, 1227–1230 (2002).

71. Nimmerjahn, F. et al. Detection of wild type and deleted latent membrane protein 1 (LMP1) of Epstein-Barr virus in clinical biopsy material. *J. Virol. Methods* 116, 1227–1230 (2004).

72. Schwieger, M. et al. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. *J. Exp. Med.* 196, 1227–1240 (2002).

73. Nicholls, J. et al. Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta. *J. Biol. Chem.* 282, 8724–8733 (2007).

74. Kavathas, P., Bach, F. H. & DeMars, R. Gamma ray-induced loss of expression of HLA and glyoxalase I alleles in lymphoblastoid cells. *Proc. Natl Acad. Sci. USA* 77, 4251–4255 (1980).

75. Marchini, A., Longnecker, R. & Kieff, E. Epstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants. *J. Virol.* 66, 4972–4981 (1992).

76. Nimmerjahn, F. et al. Active NF-kappaB signalling is a prerequisite for influenza virus infection. *J. Gen. Virol.* 85, 2347–2356 (2004).

77. Rancan, C., Schirrmann, L., Huls, C., Zeidler, R. & Moosmann, A. Latent membrane protein LMP2A impairs recognition of EBV-infected cells by CD8+ T cells. *PLoS Pathog.* 11, e1004906 (2015).

78. Ceci, J. D. et al. Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. *Genes Dev.* 11, 688–700 (1997).

79. Heissmeyer, V., Krappmann, D., Walczyn, F. G. & Scheidereit, C. NF-kappaB latency III-infected cells. *J. Virol.* 78, 1227–1230 (2002).

80. Schwieger, M. et al. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. *J. Exp. Med.* 196, 1227–1240 (2002).

81. Nicholls, J. et al. Detection of wild type and deleted latent membrane protein 1 (LMP1) of Epstein-Barr virus in clinical biopsy material. *J. Virol. Methods* 116, 1227–1240 (2004).

82. Kieser, A. Assaying the activity of kinases regulated by LMP1. *Methods Mol. Biol.* 174, 325–336 (2001).

Acknowledgements
We thank Helmut Kurtz and Qimei Yang for excellent technical assistance. We further thank Marc Schmidt-Supprian and Josef Maunser for cell lines, Christopher Baum, Ted Dawson, Daniel Krappmann and Christos Patriotis for plasmids, Elisabeth Kremmer and Regina Feederle for antibodies, and Joachim Ellwart for help with fibroblast cell sorting. This work was supported by grants Ki 825/1–3 of the German Research Foundation (DFG), e: Med 031A428G by the Federal Ministry of Education and Research, and TTU 07.802 and TTU 07.809 by the German Research Center for Infection Research (DFZIF) to A.K.

Author contributions
A.K. designed and supervised the project, conducted experiments, analysed and interpreted data and wrote the manuscript. S.V. conducted experiments, analysed and interpreted data and wrote the manuscript. K.R.S. and F.G. conducted experiments, analysed and interpreted data, A.-W.M. conducted experiments, J.B.W. contributed materials and interpreted data, A.M. contributed materials, conducted experiments, and interpreted data.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-020-14502-x.

Correspondence and requests for materials should be addressed to A.K.

Peer review information *Nature Communications* thanks Bill Sugden and the other anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2020